In pre-clinical mouse models anti-sclerostin antibodies prevented bone loss and increased fracture resistance, which was further enhanced by combining with zoledronate (53, 54), making Romosozumab an attractive treatment for myeloma bone disease. The gene discussed is SOST; the disease is plasma cell myeloma.